PL2365988T3 - Usieciowane polimery kationowymienne, kompozycje i zastosowanie w leczeniu hiperkaliemii - Google Patents

Usieciowane polimery kationowymienne, kompozycje i zastosowanie w leczeniu hiperkaliemii

Info

Publication number
PL2365988T3
PL2365988T3 PL09748557T PL09748557T PL2365988T3 PL 2365988 T3 PL2365988 T3 PL 2365988T3 PL 09748557 T PL09748557 T PL 09748557T PL 09748557 T PL09748557 T PL 09748557T PL 2365988 T3 PL2365988 T3 PL 2365988T3
Authority
PL
Poland
Prior art keywords
compositions
cation exchange
crosslinked cation
exchange polymers
treating hyperkalemia
Prior art date
Application number
PL09748557T
Other languages
English (en)
Other versions
PL2365988T5 (pl
Inventor
Han-Ting Chang
Dominique Charmot
Mingjun Liu
WERNER STRüVER
Paul Mansky
Detlef Albrecht
Michael Burdick
Eric Connor
Sherin Halfon
I-Zu Huang
Ramakrishnan Chidambaram
Jonathan Mills
Original Assignee
Vifor Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41707686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2365988(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor Int Ltd filed Critical Vifor Int Ltd
Publication of PL2365988T3 publication Critical patent/PL2365988T3/pl
Publication of PL2365988T5 publication Critical patent/PL2365988T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/22—Esters containing halogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
PL09748557T 2008-08-22 2009-08-22 Usieciowane polimery kationowymienne, kompozycje i zastosowanie w leczeniu hiperkaliemii PL2365988T5 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US9109708P 2008-08-22 2008-08-22
US9112508P 2008-08-22 2008-08-22
US9111008P 2008-08-22 2008-08-22
US16589409P 2009-04-01 2009-04-01
US16589909P 2009-04-01 2009-04-01
US16590509P 2009-04-02 2009-04-02
PCT/US2009/054706 WO2010022383A2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
EP09748557.7A EP2365988B2 (en) 2008-08-22 2009-08-22 Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia

Publications (2)

Publication Number Publication Date
PL2365988T3 true PL2365988T3 (pl) 2015-12-31
PL2365988T5 PL2365988T5 (pl) 2019-11-29

Family

ID=41707686

Family Applications (4)

Application Number Title Priority Date Filing Date
PL15171701T PL2957286T3 (pl) 2008-08-22 2009-08-22 Kompozycje zawierające usieciowane kationowymienne polimery i zastosowanie w leczeniu hiperkaliemii
PL22211737.6T PL4201408T3 (pl) 2008-08-22 2009-08-22 Usieciowane kationowymienne polimery, kompozycje i zastosowanie w leczeniu hiperkaliemii
PL18188764.7T PL3431094T3 (pl) 2008-08-22 2009-08-22 Usieciowane kationowymienne polimery, kompozycje i zastosowanie w leczeniu hiperkaliemii
PL09748557T PL2365988T5 (pl) 2008-08-22 2009-08-22 Usieciowane polimery kationowymienne, kompozycje i zastosowanie w leczeniu hiperkaliemii

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL15171701T PL2957286T3 (pl) 2008-08-22 2009-08-22 Kompozycje zawierające usieciowane kationowymienne polimery i zastosowanie w leczeniu hiperkaliemii
PL22211737.6T PL4201408T3 (pl) 2008-08-22 2009-08-22 Usieciowane kationowymienne polimery, kompozycje i zastosowanie w leczeniu hiperkaliemii
PL18188764.7T PL3431094T3 (pl) 2008-08-22 2009-08-22 Usieciowane kationowymienne polimery, kompozycje i zastosowanie w leczeniu hiperkaliemii

Country Status (26)

Country Link
US (4) US20110236340A1 (pl)
EP (4) EP4201408B1 (pl)
JP (7) JP5756403B2 (pl)
KR (5) KR102150184B1 (pl)
CN (2) CN102202670B (pl)
AU (1) AU2009282721B2 (pl)
BR (1) BRPI0917853C1 (pl)
CA (1) CA2735058C (pl)
CY (3) CY2018002I1 (pl)
DE (1) DE112009002063T5 (pl)
DK (3) DK3431094T3 (pl)
ES (4) ES2545887T5 (pl)
FI (1) FI3431094T3 (pl)
GB (4) GB2495427B (pl)
HR (4) HRP20250774T1 (pl)
HU (4) HUE025934T2 (pl)
LT (4) LT3431094T (pl)
LU (1) LUC00094I2 (pl)
MX (3) MX2011001893A (pl)
NL (1) NL300962I2 (pl)
NO (2) NO2018004I1 (pl)
PL (4) PL2957286T3 (pl)
PT (3) PT2957286T (pl)
SI (2) SI3431094T1 (pl)
SM (2) SMT201800660T1 (pl)
WO (1) WO2010022383A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8574716B2 (en) * 2006-01-23 2013-11-05 Hitachi Chemical Co., Ltd. Ionic polymer devices and methods of fabricating the same
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
EP4201408B1 (en) 2008-08-22 2025-06-25 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
TR201807469T4 (tr) * 2010-03-20 2018-06-21 Relypsa Inc Polifloroakrilat partikülleri hazırlamaya yönelik kesintisiz işlem.
CA2827056C (en) 2011-02-11 2020-07-14 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
CN108276277A (zh) 2011-06-27 2018-07-13 瑞立普萨公司 丙烯酸酯及衍生物的氟化
CN110028603A (zh) * 2011-06-27 2019-07-19 瑞立普萨公司 用于将聚合酯转化为聚合酸的方法
IN2015DN01369A (pl) * 2012-07-19 2015-07-03 Relypsa Inc
EP2882798B1 (en) * 2012-08-09 2019-05-08 Patheon Austria GmbH & Co KG Process for drying polymeric materials
ES3059226T3 (en) 2012-10-08 2026-03-19 Vifor Int Ltd Potassium-binding agents for treating hypertension and hyperkalemia
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
CN105473151B (zh) * 2013-04-05 2018-09-18 Zs制药公司 用于减少钾和治疗慢性肾病和/或慢性心脏病的微孔硅酸锆和利尿药
KR102674230B1 (ko) * 2014-12-23 2024-06-11 알데릭스, 인코포레이티드 고칼륨혈증의 치료를 위한 조성물 및 방법
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
US9592253B1 (en) 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
ITUB20159278A1 (it) 2015-12-23 2017-06-23 Rjw Pharma Llc Procedimento per la sintesi di patiromer
WO2019220450A1 (en) 2018-05-16 2019-11-21 Solara Active Pharma Sciences Limited Process for preparation of patiromer
MX2021011044A (es) * 2019-03-13 2021-10-13 Astrazeneca Ab Agentes de union a potasio para su uso en pacientes de hemodialisis.
CN114867710B (zh) * 2019-11-14 2026-03-13 维福(国际)有限公司 2-氟代丙烯酸烷基酯的一步合成
US12522682B2 (en) 2020-03-27 2026-01-13 Vifor (International) Ltd. Synthesis of methyl 2-fluoroacrylate
WO2023035274A1 (en) * 2021-09-13 2023-03-16 Waterstone Pharmaceuticals(Wuhan) Co., Ltd. Polymer medicament for treating hyperkalemia and preparation method thereof
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof
CN114369729B (zh) * 2021-12-28 2023-11-03 江苏容汇通用锂业股份有限公司 一种利用锂矿渣进行浸出液除钾的工艺
CN114394918B (zh) * 2022-01-19 2023-10-20 罗长青 一种2-[[三(羟甲基)甲基]氨基]乙磺酸的制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611730A (en) * 1950-09-02 1952-09-23 Simth Kline & French Lab Medical preparation for reducing the body level of sodium
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
NL137053C (pl) † 1967-01-30
FR2171934B1 (pl) * 1972-02-16 1974-09-13 Rhone Poulenc Sa
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4470975A (en) * 1977-10-21 1984-09-11 The Johns Hopkins University Method and composition for the elimination of water from an animal body
US4380590A (en) * 1978-09-19 1983-04-19 Rohm And Haas Company Emulsion copolymer cation exchange resins
DE2846187A1 (de) † 1978-10-24 1980-05-08 Bayer Ag Kunstharze auf basis vernetzter mischpolymerisate aus mono- und polyvinylverbindungen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US5186937A (en) * 1985-06-07 1993-02-16 A.E.C. Societe De Chimie Organique Et Biologique Composition for feeding ruminants
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
JPS63218713A (ja) * 1987-02-17 1988-09-12 Daikin Ind Ltd α−フルオロアクリル酸系重合体ならびに用途
US4837015A (en) * 1987-03-05 1989-06-06 Carolina Medical Products Company, Inc. Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8829088D0 (en) † 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
DE3928990A1 (de) 1989-09-01 1991-03-07 Bayer Ag Verfahren zur herstellung von (alpha)-fluoroacrylsaeurederivaten
US5112993A (en) 1989-11-14 1992-05-12 E. I. Du Pont De Nemours And Company Process for the preparation of difluoromaleic anhydride
US5091175A (en) * 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
DE69016014T2 (de) * 1990-07-04 1995-08-31 Marcin Krotkiewski Blutdrucksenkendes Präparat.
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5281631A (en) * 1991-12-20 1994-01-25 Arch Development Corp. Phosphonic acid based ion exchange resins
DE69306844T2 (de) † 1992-04-10 1997-07-10 Mitsubishi Chem Corp Verfahren zur Herstellung von kugelförmigen vernetzten Acrylnitril-Copolymerisaten
DK0656029T3 (da) * 1992-08-20 1999-02-15 Du Pont Tværbundne polymere ammoniumsalte
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995014531A1 (en) * 1993-11-25 1995-06-01 Salternate B.V. Particles for binding monovalent cations, use of such particles as well as methods for scavenging and removing sodium and/or potassium ions
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
KR100440544B1 (ko) * 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6294163B1 (en) * 1998-10-02 2001-09-25 Geltex Pharmaceuticals, Inc. Polymers containing guanidinium groups as bile acid sequestrants
US6558665B1 (en) * 1999-05-18 2003-05-06 Arch Development Corporation Encapsulating particles with coatings that conform to size and shape of the particles
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
DE19951116A1 (de) 1999-10-23 2001-04-26 Bosch Gmbh Robert Relais, insbesondere für eine Startvorrichtung
DE19962935A1 (de) † 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Herstellung von vernetzten Ionenaustauschern auf Basis von ungesättigten, aliphatischen Nitrilen
US20030027789A1 (en) * 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
WO2002009734A1 (en) * 2000-08-01 2002-02-07 Oryza Oil & Fat Chemical Co.,Ltd. Sugar absorption inhibitors and process for producing the same
US6908609B2 (en) * 2000-11-20 2005-06-21 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US7033639B2 (en) * 2001-05-16 2006-04-25 Rohm And Haas Company Polyaniline coating composition
US6881484B2 (en) * 2001-05-30 2005-04-19 Mitsubishi Kagaku Iatron, Inc. Core-shell particle including signal-generating substance enclosed therein and process for producing the same
CA2516457C (en) * 2003-02-25 2011-12-06 Finnfeeds Finland Oy A simulated moving bed system and process
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US7556799B2 (en) † 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
KR101153035B1 (ko) 2004-03-30 2012-06-11 리립사, 인크. 이온 결합 조성물
US7429394B2 (en) * 2004-03-30 2008-09-30 Relypsa, Inc. Ion binding compositions
CN101321519A (zh) * 2005-09-30 2008-12-10 伊立普萨公司 制备含有交联壳的核-壳型复合物的方法及其得到的核-壳型复合物
WO2007038801A2 (en) † 2005-09-30 2007-04-05 Ilypsa, Inc. Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof
JP2009510126A (ja) * 2005-09-30 2009-03-12 レリプサ， インコーポレイテッド 哺乳類の胃腸管からカリウムイオンを選択的に除去するための方法および組成物
JP2010538016A (ja) * 2007-08-29 2010-12-09 ソーベント セラピューティクス インコーポレイテッド 異なる対イオン含有量を有する吸収性ポリマー組成物、ならびにその調製および使用の方法
US20100111892A1 (en) * 2008-08-22 2010-05-06 Relypsa, Inc. Crosslinked polyfluoroacrylic acid and processes for the preparation thereof
EP4201408B1 (en) † 2008-08-22 2025-06-25 Vifor (International) Ltd. Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
WO2010022380A2 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
WO2010022381A1 (en) * 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties

Also Published As

Publication number Publication date
GB2495428A (en) 2013-04-10
CY1120930T1 (el) 2020-05-29
LUC00094I1 (pl) 2018-12-19
PT3431094T (pt) 2023-03-03
HUE025934T2 (en) 2016-05-30
EP4201408B1 (en) 2025-06-25
BRPI0917853A2 (pt) 2015-11-24
DK3431094T3 (da) 2023-02-20
JP2014144978A (ja) 2014-08-14
US20220000906A1 (en) 2022-01-06
GB201222750D0 (en) 2013-01-30
ES2939021T3 (es) 2023-04-18
EP2365988B1 (en) 2015-07-22
EP2365988B2 (en) 2019-07-03
HRP20181961T1 (hr) 2019-02-08
JP6890116B2 (ja) 2021-06-18
GB201222752D0 (en) 2013-01-30
KR20200029614A (ko) 2020-03-18
KR20180014845A (ko) 2018-02-09
GB2495426A (en) 2013-04-10
CY2018002I1 (el) 2019-07-10
NO2018004I1 (no) 2018-01-17
GB2475657A (en) 2011-05-25
EP2957286A1 (en) 2015-12-23
PL2957286T3 (pl) 2019-03-29
PL2365988T5 (pl) 2019-11-29
JP2016145256A (ja) 2016-08-12
GB2495427B (en) 2013-08-07
SMT201500207T1 (it) 2015-10-30
KR101825113B1 (ko) 2018-02-02
DK2957286T3 (en) 2018-12-17
PT2365988E (pt) 2015-10-22
FI3431094T3 (fi) 2023-03-20
HRP20250774T1 (hr) 2025-08-29
SMT201800660T1 (it) 2019-01-11
GB2475657B (en) 2013-05-29
JP5756403B2 (ja) 2015-07-29
WO2010022383A3 (en) 2010-09-23
JP2020172537A (ja) 2020-10-22
MX2011001893A (es) 2011-09-27
CY2019002I2 (el) 2020-05-29
GB201104561D0 (en) 2011-05-04
US20200289550A1 (en) 2020-09-17
MX389664B (es) 2025-03-20
KR102150184B1 (ko) 2020-08-31
CA2735058C (en) 2021-01-26
HUE071829T2 (hu) 2025-09-28
HRP20150955T1 (hr) 2015-10-09
KR20200128600A (ko) 2020-11-13
LTPA2018004I1 (lt) 2018-02-12
EP4201408A1 (en) 2023-06-28
US20110236340A1 (en) 2011-09-29
ES3034535T3 (en) 2025-08-19
LUC00094I2 (pl) 2020-01-23
SI2957286T1 (sl) 2018-12-31
AU2009282721B2 (en) 2015-10-29
EP4201408C0 (en) 2025-06-25
JP6232468B2 (ja) 2017-11-15
MX364398B (es) 2019-04-24
JP6633583B2 (ja) 2020-01-22
NO2018041I1 (pl) 2018-12-14
LT2957286T (lt) 2018-12-10
KR20180133561A (ko) 2018-12-14
EP3431094B1 (en) 2022-12-07
BRPI0917853C1 (pt) 2021-05-25
BRPI0917853B1 (pt) 2020-04-07
NL300962I1 (nl) 2018-12-28
JP5883471B2 (ja) 2016-03-15
GB2495427A (en) 2013-04-10
HUS1900003I1 (hu) 2019-02-28
US20170165292A1 (en) 2017-06-15
SI3431094T1 (sl) 2023-04-28
EP3431094A1 (en) 2019-01-23
EP2365988A2 (en) 2011-09-21
WO2010022383A2 (en) 2010-02-25
CA2735058A1 (en) 2010-02-25
LT3431094T (lt) 2023-02-27
CN103919792B (zh) 2018-03-09
HUE061320T2 (hu) 2023-06-28
DK2365988T4 (da) 2019-10-07
PL4201408T3 (pl) 2025-09-22
KR102300471B1 (ko) 2021-09-30
PT2957286T (pt) 2018-11-30
DK2365988T3 (en) 2015-10-26
JP2019065030A (ja) 2019-04-25
JP2012500806A (ja) 2012-01-12
KR101928973B1 (ko) 2018-12-13
NL300962I2 (nl) 2020-06-02
ES2545887T5 (es) 2020-02-17
PL3431094T3 (pl) 2023-04-24
ES2699494T3 (es) 2019-02-11
LTPA2018016I1 (lt) 2019-01-10
KR102178208B1 (ko) 2020-11-12
JP2014144977A (ja) 2014-08-14
DE112009002063T5 (de) 2012-01-12
HK1184675A1 (en) 2014-01-30
JP2017218454A (ja) 2017-12-14
GB201222749D0 (en) 2013-01-30
CY2019002I1 (el) 2020-05-29
AU2009282721A1 (en) 2010-02-25
HRP20230091T1 (hr) 2023-03-17
KR20110063647A (ko) 2011-06-13
CN103919792A (zh) 2014-07-16
BRPI0917853B8 (pt) 2020-04-22
LTC2957286I2 (lt) 2019-11-25
CN102202670B (zh) 2014-04-30
ES2545887T3 (es) 2015-09-16
EP2957286B1 (en) 2018-11-21
CN102202670A (zh) 2011-09-28

Similar Documents

Publication Publication Date Title
HRP20181961T1 (hr) Pripravci koji sadrže umrežene polimere za kationsku izmjenu i primjena u liječenju hiperkalijemije
EP2315796A4 (en) COMPOSITION OF RETICULATED POLYMERS
GB0902052D0 (en) Polymers,composition and use
EP2074250A4 (en) COMPLETE SYSTEM FOR WASH TREATMENT
PL2315773T3 (pl) Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy
IL205939A (en) Compounds for use in the treatment of lysosomal disorders
IL201593A0 (en) Compositions comprising adenosine deaminase for use in treating tumors
ZA201006177B (en) Specific polyisobutene amines, and use thereof as detergents in fuels
EP2042615A4 (en) BRAKE DISCS WITH EXCELLENT RESISTANCE TO ANNEALING AND EXCELLENT TENACITY
HUS1800004I1 (hu) Térhálósított kationcserélõ polimerek, az ezeket tartalmazó készítmények és alkalmazásuk hiperkalémia kezelésére
SI2365988T1 (sl) Zamreženi polimeri za kationsko izmenjavo, sestave in uporaba pri zdravljenju hiperkaliemije
HK1158093B (en) Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
HK1158093A (en) Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
HK1184675B (en) Crosslinked cation exchange polymers, compositions and use in treating hyperkalemia
GB2457926B (en) Improvements in heat exchange systems
GB0702050D0 (en) Improvements in water treatment systems
GB0800718D0 (en) Treating solid surfaces